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In the Swiss HIV Cohort Study, the number of people who 
inject drugs with replicating hepatitis C virus (HCV) infection 
decreased substantially after the introduction of direct-acting 
antivirals (DAAs). Among men who have sex with men, the 
increase in DAA uptake and efficacy was counterbalanced by 
frequent incident HCV infections.
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Hepatitis C virus (HCV) infection is a major cause of liver 
cancer and mortality among HIV-infected patients [1]. 
Achieving a sustained virological response (SVR) substan-
tially reduces HCV-related mortality and morbidity and 
prevents further HCV transmission [2]. After the approval 
of interferon-free second-generation direct-acting antivi-
rals (DAAs) in Switzerland, we observed a 4-fold increase 
in treatment uptake and a 2-fold increase in treatment effi-
cacy, with an SVR rate above 90% across all HCV genotypes 
[3]. Previous modeling studies indicated that a major 
increase in DAA treatment uptake has the potential to curb 
the HCV epidemic [4, 5]. But depending on risk behavior 
and background prevalence, this may not be sufficient to 
reduce HCV incidence and prevalence among all people 
living with HIV (PLWH) [5]. In populations with increas-
ing risk behavior, the impact of treatment upscale can be 
counterbalanced by frequent incident infections. Such is 
the case among HIV-infected men who have sex with men 
(MSM), for whom a substantial decrease in the number of 
people with replicating HCV infection may not occur des-
pite treatment upscale [4].
Understanding the trends in the number of PLWH with 
replicating HCV infection in key populations is paramount 
to achieving the World Health Organization elimination 
targets by 2030 (www.who.int/hepatitis/publications/glob-
al-hepatitis-report2017/en). The aim of this study was to 
describe and compare DAA upscale and its impact on the 
number of replicating HCV infections among people who 
inject drugs (PWID) and MSM. The Swiss HIV Cohort Study 
(SHCS) provides an optimal framework to address these 
trends in routine clinical practice in a nationwide represent-
ative population.
METHODS
All MSM and PWID enrolled in the SHCS (www.shcs.ch) with 
follow-up between June 2005 and June 2016 were included. 
Detailed clinical and laboratory data were recorded at study 
entry and every 6 months thereafter. HCV infection assessments 
included yearly serology followed by HCV RNA determination 
in seropositive individuals, as well as a detailed treatment his-
tory, as described previously [3].
We estimated the absolute number of prevalent and incident 
(primary and re-infections) HCV infections over time among 
PWID and MSM separately. For incident infections, we also cal-
culated incidence as events per 100 patient-years of individual 
follow-up time:
Prevalent HCV Infection
Positive HCV serology with detectable HCV viral load (VL) at 
registration in the SHCS.
Incident Primary HCV Infection
New positive HCV serology with a previous negative HCV 
serology.
Incident HCV Re-infection
Detectable HCV VL measurement after a patient had achieved 
spontaneous clearance or SVR (see definition below). Patients 
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were considered at risk of re-infection following HCV clearance 
and until the last available HCV RNA measurement.
Temporal trends in distribution of patients across the fol-
lowing 3 categories were assessed at weekly intervals as fol-
lows: The number of patients with replicating HCV infection 
was estimated as the sum of patients with prevalent and inci-
dent HCV infections at every time point. Spontaneous clear-
ance was defined as 2 consecutive undetectable HCV VLs 
within 6 months after a positive HCV VL measurement with-
out a history of HCV treatment, or a positive HCV serology 
at enrollment in the SHCS and undetectable HCV VL in the 
first available measurement. Sustained virological response was 
defined as undetectable HCV VL for at least 6  months after 
successful antiviral therapy of a replicating HCV infection 
with either interferon-based or DAA-based therapy.
We estimated the incidence of HCV treatment for the study 
period stratified by type of treatment (DAA-based therapy vs 
treatment with pegylated interferon/ribavirin) and HIV trans-
mission group (PWID vs MSM). All calculations were per-
formed using R.
RESULTS
Five thousand two hundred sixty-seven MSM and 1805 PWID 
were followed by the SHCS over the study period, resulting 
in 38 693 and 14 748 person-years of follow-up for MSM and 
PWID, respectively (Supplementary Figure 1). Of those, 1455 
PWID and 314 MSM had a positive HCV serology and at least 1 
RNA measurement during follow-up. Median follow-up (IQR) 
was 11.1 (5.0–11.4) years for PWID and 5.4 (2.5–9.9) years 
for MSM. Sixteen MSM and 330 PWID died during the study 
period. The incidence of interferon-based therapy initiation 
was higher in MSM (11.1/100 person-years [py]) than in PWID 
(4.1/100 py) and dropped to almost 0 in 2015 in both groups 
(Figure 1A). DAAs were approved in Switzerland in April 2014. 
At the time, treatment was restricted to patients with advanced 
fibrosis or cirrhosis (Metavir ≥F3) or defined extrahepatic man-
ifestation of chronic HCV infection. In August 2015, the thresh-
old was reduced to Metavir F2. At the start of the DAA era, 19% 
of PWID and 17% of MSM had an advanced liver fibrosis or 
cirrhosis and thus fulfilled the fibrosis requirements for reim-
bursement. The incidence of DAA treatments increased rapidly 
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Figure 1. A, Direct-acting antiretroviral (DAA)– and interferon-based treatment uptake (incidence). B, Number and distribution of new hepatitis C virus (HCV) infections. 
C, Distribution of people who inject drugs (PWID) and men who have sex with men (MSM) among spontaneous clearers, treatment-induced clearance (sustained virological 
response [SVR]), and replicating infection (RNA+).
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from 2012 on and reached 28.3 and 17.6/100 py for PWID and 
MSM, respectively, in 2016.
The number of incident primary HCV infections during the 
study period was much higher among MSM than PWID (inci-
dent primary infections: 159 in MSM vs 8 in PWID) (Figure 1B). 
In MSM, the incidence of primary infections increased from 
0.2/100 (95% CI: 0.1–0.5) to 0.9/100 (95% CI: 0.4–1.9) py. In 
PWID, there was only 1 case of primary infection since 2012. 
The incidence of reinfection increased in MSM (from 0/100 
[95% CI:  0–242.3] to 9.5/100 [95% CI:  0.2–53.1]), whereas it 
decreased 3-fold in PWID (from 13/100 [95% CI: 2.7–38.0] to 
4.7/100 [95% CI: 0.6–16.8]). The total numbers of reinfections 
were 17 and 28 among MSM and PWID, respectively.
Figure  1C shows the distribution of HCV-infected patients 
among the 3 categories (spontaneous clearance, SVR, and rep-
licating HCV infection) over the study period. Although the 
number of patients with replicating HCV infection consistently 
declined in PWID (from 889 to 351), it increased in MSM (from 
62 to 110). From October 2014 onwards, we noticed a faster 
decline in the number of patients with replicating HCV infec-
tion in PWID (indicated with the dashed grey line in Figure 1C). 
Between October 2015 and the end of the study period (May 
31, 2016), the number of PWID with replicating HCV infection 
decreased at an approximate rate of 129 patients per year (from 
525 to 314). In contrast, the number of MSM with replicating 
HCV remained stable over the same period.
DISCUSSION
The trends in the number of patients with replicating HCV 
infection differed substantially between PWID and MSM in 
this nationwide representative cohort study. Among PWID, the 
introduction of DAAs boosted the already ongoing decline in 
the burden of HCV infection. In MSM, the increase in treat-
ment uptake and efficacy after introduction of DAAs was 
counterbalanced by high numbers of primary and re-infec-
tions. Accordingly, the introduction of DAAs did not result in a 
decline in the number of MSM with replicating HCV infection.
In PWID, the number of new HCV infections steadily 
declined over time. We previously reported a decrease in HCV 
incidence in this population [6]. This can be mainly attributed 
to the success of opioid and needle exchange programs. In line 
with previous studies [7], we also observed a 3-fold decline in 
re-infections, resulting in a decreased rate (4.7/100 [95% CI: 
0.6–16.8] py) at the end of the study period, as well as very few 
primary infections (1 since 2012). The low rate of incident HCV 
and HIV infections and treatment upscale in recent years con-
tributed to a substantial decline in the number of patients with 
replicating infection. The rapid upscale of treatment among 
PWID might have a population-level prevention benefit by 
reducing the reservoir of HCV viremic persons. Our study 
lines up with previous modeling work suggesting that treat-
ment upscale among PWID combined with harm reduction 
programs would substantially reduce the number of patients 
with replicating HCV infection [8].
HCV has continued to spread among HIV-infected MSM in 
recent years, although the total number of patients with repli-
cation infection remains significantly lower than among PWID 
[9]. In the SHCS, HCV incidence increased substantially in 
MSM whereas it declined in PWID [6]. The increase has been 
linked to changes in sexual risk behavior and recreational drug 
use. During the study period, we observed a high number of 
primary HCV infections, and the incidence of HCV re-infec-
tions increased and reached 9.5/100 (95% CI:  0.4–1.9) py at 
the end of the study period. Ingiliz et al. found a re-infection 
incidence of 7.3/100 (95% CI:  6.2–8.6) among HIV-positive 
MSM, with 25% being re-infected at 3  years [10]. Our previ-
ous modeling studies indicated that treatment upscale would 
reduce HCV infection incidence and prevalence if risk behavior 
stabilized or decreased [5]. The current study demonstrates that 
the number of patients with replication HCV infection did not 
decrease despite an increase in treatment-induced HCV cure 
after the introduction of DAAs.
Until recently, reimbursement for DAAs was restricted to 
those with significant fibrosis in Switzerland and many other 
countries. At the start of the DAA era, less than 20% of individ-
uals fulfilled the fibrosis reimbursement criteria, with no sig-
nificant differences between MSM and PWID. This limitation 
substantially prolongs the time individuals spend with replicat-
ing HCV infection. This may have led to further HCV trans-
missions among HIV-infected MSM with high-risk behavior 
and might have contributed to the lack of decline in the number 
of replicating HCV infections observed in this study. The Swiss 
HCVree trial (ClinicalTrials.gov: NCT02785666) investigates 
the impact of an intensive HCV RNA–based screening, treat-
ment irrespective of fibrosis stage, and behavioral intervention 
on HCV prevalence and incidence in MSM participating in the 
SHCS [11]. The experience from the Netherlands indicates that 
a massive treatment scale-up could indeed reduce HCV inci-
dence in this population [12]. Future analyses will reveal to 
what extent intensified treatment and risk reduction decrease 
the burden of HCV infection among MSM.
Our study was strengthened by the availability of long-term 
data on HCV replication and treatment in a large, nationwide 
representative cohort study. We were able to assess long-term 
trends in the number of patients with replicating HCV infec-
tion in a clinical routine situation. Our study has limitations. 
Re-infections were assessed in clinical routine following inter-
national guidelines, but not according to a standardized pro-
tocol for repeated HCV RNA screening. Therefore, the rate 
of re-infections could have been underestimated. In addition, 
the number of patients who died or left the cohort was higher 
among PWID than MSM, which makes it difficult to compare 
both groups with regard to the number of patients with replicat-
ing HCV infection.
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In conclusion, the increase in treatment uptake and efficacy 
observed after the approval of DAAs boosted the decline of rep-
licating HCV infections among PWID in the SHCS. However, 
among MSM, the potential beneficial impact of new treatments 
was counterbalanced by the high rate of incident HCV infec-
tions and by postponing treatment because of reimbursement 
limitations.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
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sponding author.
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